[1] Sancken U,Bahner D. Comparison of triple-risk assessment of fetal trisomy 21 including total human choriogonadotropin(hCG) or its free beta-subunit (free beta hCG) [J]. Fetal Diagn Ther,2003,18(2):122-127. [2] 顾蔚蓉,李笑天,严英榴,等. 产前诊断中胎儿超声软指标阳性的临床处理与预后分析 [J]. 复旦学报:医学版,2010,37(2):180-183. [3] Lima FA,Moreira-Filho CA,Ramos PL,et al. Decreased AIRE expression and global thymic hypofunction in Down syndrome [J]. J Immunol,2011,187(6):3422-3430. [4] 季星. 唐氏综合征产前筛查 [J]. 临床儿科杂志,2013,12 (31):1190-1192. [5] Falcon O,Auer M,Gerovassili A,et al. Screening for trisomy 21 by fetal tricuspid regurgitation,nuchal translucency and maternal serum free beta-hcG and PAPP-A 11+0 to13+6 weeks [J]. Ultrasound Obstet Cynecal,2006,27(2):151-155. [6] Locatelli A,Piccoli MG,Vergani P. Critical appraisal of the use of nuchal fold thickness measurements for the prediction of Down syndrome [J]. Am J Obstet Gynecol,2000 ,182(1 Pt 1):192-197. [7] Van den Hof MC,Wilson RD. Fetal soft markers in obstetric ultrasound [J]. J Obstet Gynaecol Can,2005,27(6):592-636. [8] 梁雄,朱锋,朱兰芳,等. 3195例孕中期唐氏综合征的血清筛查和产前诊断临床分析[J]. 中国现代医学杂志,2005,15(20):3079-308.